Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx
详细信息 查看全文
- 作者：Joã ; o Carlos da Silva Bizario ; Daniel Giuliano Cerri ; Lilian Cataldi Rodrigues ; Gislane L.V. Oliveira ; Auro Nomizo ; Daniela Dover de Araujo ; Paula Sakemi Fukuhara ; Juliana Caldas Ribeiro ; Fabí
- 关键词：Duchenne muscular dystrophy ; mdx mice ; Imatinib mesylate ; Fibrosis ; Immunomodulation ; Transforming growth factor-β ; 1
- 刊名：Journal of Neuroimmunology
- 出版年：2009
- 出版时间：25 July 2009
- 年：2009
- 卷：212
- 期：1-2
- 页码：93-101
- 全文大小：558 K
文摘
Myofiber degeneration, inflammation, and fibrosis are remarkable features of Duchenne muscular dystrophy. We hypothesized that the administration of imatinib mesylate, an inhibitor of tyrosine kinase and TGF-β pro-fibrogenic activity, could improve the muscular conditions in mdx mice. Four-week old mdx mice were treated and exercised for 6 weeks. Gastrocnemius and diaphragm histopathology, strength, creatine kinase, and cytokine levels were evaluated. The treated group presented increased muscular strength and decreased CK levels, injured myofibers, and inflammatory infiltrates. Pro-inflammatory cytokines and TGF-β were also reduced, while IL-10 was increased, suggesting an immunomodulatory effect of imatinib, which can ameliorate the dystrophic phenotype in mdx mice.